VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
The primary objective of the study is to compare the efficacy of the probiotic VSL#3 versus placebo, in addition to standard maintenance drugs, in maintaining remission in Crohn\'s disease (CD). The secondary objectives are: * To determine the time till flare of CD patients on VSL#3 compared to placebo. * To assess whether concurrent therapy with VSL#3 leads to an improvement in the quality of life (QOL). * To assess whether concurrent therapy with VSL#3 reduces the severity of a flare if it occurs.
Epistemonikos ID: f1a27827deb1b9db8cfe27203ec8ce6fd35cd462
First added on: Mar 23, 2022